Airline Passenger Capacity is Projected to Grow at 47% in 2022
Global aviation analytics firm Cirium, has released its second annual Airline Insights Review, which reveals an industry in recovery and poised for a projected 47% growth in capacity (the number of seats flown) in 2022. This steep increase indicates capacity could return to 2015 levels by the end of next year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005398/en/
Airlines are poised for a projected 47% growth in capacity (by seats flown) in 2022, as revealed in Cirium's new Airline Insights Review. (Graphic: Business Wire)
Last year, the pandemic and its consequences wiped out 15 years of global passenger capacity growth—based on the total number of seats flown—in a matter of months, reducing 2020 capacity flown to levels last seen in 2005.
Although recovery was varied in 2021, global capacity is forecasted to return to capacity levels seen in 2006 by the end of the year.
Regions with strong domestic markets showed accelerated recovery this year—in particular, in the US and China. In fact, Chinese domestic flights are up 6% compared to pre-pandemic levels in 2019.
Of all the flights tracked January to October 31 worldwide, 78% were domestic flights. International flights experienced a slow recovery with many restrictions in place until Q4 of 2021, and some restrictions still in place, depending on the routes. Indeed, international flights saw a 6% growth in 2021 compared to the same period in 2020.
“The past year has had its challenges as we continued to face fluctuating cases of COVID-19, new variants—most recently Omicron—and varied vaccination programs per country. There is light at the end of the tunnel as we see international travel corridors reopening. However, we will continue to track this momentum as new variants arise and we hope the invaluable analyses in our Airline Insights Report help to navigate what’s to come,” said Jeremy Bowen, CEO of Cirium.
Cirium predicts a year of acceleration in 2022
“Cirium’s experts have analysed 2021 data and formulated forecasts for 2022 and beyond. Near the end of 2022, global capacity will return to 2015 levels, as we see a steep increase in more seats returning to the skies.
“In Cirium’s Airline Insights Report, we have included Seven Things to Look for in 2022 to enable the industry to gain insight into these forecasts and use them to anticipate market developments and make well-informed decisions,” Bowen added.
As more passengers steadily return to the skies, this will mean worldwide domestic traffic (measured in passenger numbers) is predicted to be back to pre-pandemic levels by the end of 2022. International passenger traffic is likely to reach two-thirds of 2019 levels.
Cirium projections show that the global passenger fleet in service will increase to 20,700 by the end of 2022—only a few hundred less than at the end of 2019—pre-pandemic.
The slow recovery of business travel seen so far will change in 2022, with predictions from the industry that there will be a 36% surge in business travel year-over-year. According to Cirium data, business events being tracked online are already increasing for next year.
Conversions of passenger jets to freighters will continue to increase and in 2022, with a potential total of 160 passenger jets converted to freighters—surpassing previous conversion figures.
Aircraft values and lease rates took an unprecedented hit in the past 12 months, however Cirium suggests that they’ve reached the bottom as the values and lease rates for many aircraft types have stabilized and a few are improving. Some aircraft types remain on watch next year, including the Airbus A350 and the Boeing 787.
Cirium anticipates that airlines will increasingly rely on partnerships to carry passengers into partner home markets in 2022. This will mean a shift in airlines flying secondary markets post-pandemic and instead see them taking advantage of their airline partners to fly passengers to secondary cities.
As more flights return to the skies, it’s no surprise that CO2 emissions will increase next year—the CO2 emissions from flights in 2021 were 40% less than pre-pandemic. However, airlines are returning more fuel-efficient fleets to service and sustainability has become front and center in aviation, with many looking at fuel burn and how to reach net zero 2050 targets.
“Cirium anticipates the return to normalcy will usher in more focus on sustainable travel practices, including younger, more fuel-efficient aircraft, and the ability to more closely measure the impact of airline travel on global greenhouse gas emissions,” said Bowen.
To read the full Cirium Airline Insights Review 2021, including the seven predictions of 2022 – click here.
The 2021 Airline Insights Report is Cirium’s collection of expert analyses covering a wide range of topics surrounding airlines at the core and the aviation industry that encircles them. The report covers:
- Top routes flown and airports in 2021
- The current state of the global passenger traffic, capacity and fleet
- Sustainability initiatives in the airline industry
- Airline startups and new routes flown in 2021
- Average airfares in key markets
- Spotlights on APAC and Latin America
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005398/en/
Contact information
For media enquiries:
Rachel Humphries, Cirium at media@cirium.com
Mike Arnot, Julliett Alpha at cirium@juliettalpha.com
Paul Charles/Michael Johnson/Callum McGoldrick, PC Agency at cirium@pc.agency
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
